



Universiteit
Leiden
The Netherlands

The role of microRNA-126 in vascular homeostasis

Solingen, C. van

Citation

Solingen, C. van. (2012, September 26). *The role of microRNA-126 in vascular homeostasis*. Retrieved from <https://hdl.handle.net/1887/19855>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/19855>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden




The handle <http://hdl.handle.net/1887/19855> holds various files of this Leiden University dissertation.

Author: Solingen, Coen van

Title: The role of microRNA-126 in vascular homeostasis

Date: 2012-09-26

CHAPTER I
General introduction



Introduction

Cardiovascular diseases have emerged as the leading cause of death worldwide, particularly in developed countries. The World Health Organization has estimated that in 2030, almost 23.6 million people will die from cardiovascular diseases [1]. By the time that vascular problems are detected, the underlying cause is usually quite advanced, having progressed for decades. Therefore there is an increased emphasis on altering well-known risk factors by healthy diet, exercise, and avoidance of smoking. Moreover, to understand the exact influence of environmental risk factors on our vasculature it is of high relevance to fully understand the biological mechanisms that keep our vessels healthy and functional. This thesis covers several aspects on the fundamental gene regulation that is involved in maintaining vascular homeostasis. In particular, the role of endothelial enriched miRNA-126 in, so-called, angioadaptation has been described.

Part I: Vascular homeostasis

Vascular growth and regression plays a major role in both health and disease. In physiology, it contributes to embryogenesis, development and wound healing. Furthermore, it plays a role in the pathogenesis of many disorders, either by excessive vessel growth, for example in cancer, atherosclerosis, diabetic retinopathy, psoriasis and arthritis, or by insufficient vessel growth, for example in ischemic disease of heart, limb or brain, pre-eclampsia and osteoporosis [2]. However, development and maintenance of the vascular system requires not only the formation of new vessels, but also the continuous adjustment of vessels and network structures in response to functional needs, so called, angioadaptation [3]. Three types of neovascularization can be recognized in the formation of a vascular network; angiogenesis, vasculogenesis and arteriogenesis [4]. In each of these processes a complex interplay of growth factors, cytokines and the combined action of multiple cell types is required. The basic principles of these three vascular processes will be described in more detail in the first part of this general introduction.

Vasculogenesis

During embryogenesis the first endothelial and hematopoietic cells of the yolk sac arise from a common mesodermal progenitor, the hemangioblast, located in the blood islands [5, 6]. The formation of the capillary network that arises from the yolk sac is driven by embryonic endothelial progenitor cells which are located at the outer lining of these blood islands. The process, where blood vessels are formed when there is no pre-existing capillary network, is called vasculogenesis. Once the embryonic heart has developed, the first primitive blood cells start to circulate from the yolk sac into the embryo [5, 7].

Interestingly, adult blood circulation and tissues still contain small numbers of these endothelial progenitor cells (EPCs) [8-10] and the potential contribution of these circulating progenitor cells to the formation new blood vessels has gained much interest. Next to their presence in the circulation, it has also been demonstrated that EPCs could contribute to adult neo-vascularization (Figure 1) [11-15]. Using different quantification methods, many groups have shown that the number of EPCs (classified in human by expression of the markers CD34, CD133 and KDR/VEGFR-2) in the circulation reflects or correlates with disease state. As example, lower levels of EPCs are found in people at risk for cardiovascular diseases [16-18]. On the contrary, an increase of these cells is found in patients with ischemic pathophysiology [19, 20].





Figure 1. Vasculogenesis

Vessel formation can occur by the mobilization of bone marrow-derived endothelial progenitor cells that differentiate into endothelial cells [42]. Adapted from: Molecular mechanisms and clinical applications of angiogenesis, Carmeliet & Jain, Nature 2011.

Despite extensive research, the exact mechanisms how these bone marrow-derived cells exactly contribute to the formation of new blood vessels remain unclear. EPCs are mobilized by a variety of growth factors such as stromal cell-derived factor 1 (SDF-1) and VEGF21 and may by means of these mobilizers be attracted to sites of ischemia. However, incorporation of EPCs into the endothelial layer is rarely reported [15] leaving a paracrine function of cells with secretion of angiogenic factors or a supportive function as perivascular cells more probable mechanisms [22].



Regardless of the unknown, complex mechanisms how EPCs contribute to neovascularization, strategies for a stem cell-based therapeutical approach have been set out in humans and animals. The therapeutic effectiveness after injection of human CD34+ cells or cultured EPCs upon myocardial infarction has been demonstrated in mice [23], rats [24-28], swine [26, 29] and monkeys [30]. In humans several randomized, placebo-controlled studies showed effectiveness and safety of the infusion of bone marrow cells to treat (limb) ischemia [31-33].



Angiogenesis

Angiogenesis is the formation of new capillaries from endothelial cells that sprout from pre-existing vascular network and is regulated by a variety of pro- as well as anti-angiogenic factors [34]. A trigger for angiogenesis is most often the lack of oxygen (hypoxia) that induces the availability of hypoxia inducible factor 1 alpha (HIF-1 α), a protein that is degraded when sufficient oxygen is available [35]. As a consequence HIF-1 α is able to bind its counterpart HIF-1 α . This homodimeric complex that adheres to hypoxia responsive elements in the promoter regions of target genes. As a result, elevated levels of this transcription factor complex lead to the increased production of pro-angiogenic cytokines and growth factors, such as vascular endothelial growth factor (VEGF) [36]. Subsequently, VEGF recruits myeloid cells that produce pro-angiogenic factors, like tumor necrosis factor alpha (TNF- α). Furthermore, VEGF activates endothelial cells to produce nitric oxide via endothelial nitric oxide synthase (eNOS), which induces vascular permeability [37]. Due to the increased levels of TNF- α and VEGF vascular junctions loosen and the endothelial cells detach from their neighboring cells, leading to the branching of tip cells towards the ischemic area [4, 37-39]. Endothelial cells, but also recruited inflammatory cells and fibroblasts produce proteases, such as matrix metalloproteinases (MMP) and urokinase-plasminogen activator that are essential in the degradation of the extracellular matrix and the liberation of growth factors. This degradation facilitates endothelial migration by tip and stalk cells that are essential by the formation of novel, primitive tube-like structures. Tip cells navigate in response to guiding VEGF-signals and adhere to the extracellular matrix to migrate. Stalk cells behind the tip cell proliferate, elongate and form a lumen, and sprouts fuse to establish a perfused neovessel. Proliferating stalk cells attract pericytes and deposit basement membranes to become stabilized. After fusion of neighboring branches by macrophages [40], lumen formation allows perfusion of the neovessel, re-establishment of junctions, deposition of basement membrane, maturation of pericytes and production of vascular maintenance signals (a schematic overview of angiogenesis by tip cells is shown in Figure 2). Consequently, blood will be able to flow augmenting perfusion and subsequent oxygen diffusion into the ischemic tissue [41, 42].

Therapeutically, the stimulation of angiogenesis by the administration of angiogenic growth factors into the circulation or the ischemic area is a promising approach and beneficial effects of methods using growth factors have been shown in a variety of ischemia models in animals. Early studies, where VEGF-A was used in small cohorts of patients suffering from advanced ischemic disease, were encouraging [43-46]. In contrast, larger randomized, placebo-controlled trials of therapeutic angiogenesis have been published more recently are inconsistent [47-50]. These results that have tempered the enthusiasm of developing new, single growth factor-based, angiogenic strategies. Therefore, to improve



clinically interference with angiogenesis, more information is needed on the regulation of neovascularization in ischemic tissues.

Arteriogenesis

During arteriogenesis, unlike angiogenesis and vasculogenesis, no new blood vessels are formed, but the lumen of pre-existing capillaries is widened by remodeling and the vessels become mature collaterals. When a major artery is occluded, the formation of new capillaries is not enough to support sufficient oxygen levels in the risk region. This results in a redistribution of blood flow in the pre-existing, immature collateral arterioles. The trigger for arteriogenesis comes predominantly from the mechanic stimuli derived from the elevated flow and shear stress on the vascular endothelium following upstream occlusion. Endothelial cells become activated and up-regulate surface adhesion molecules. Furthermore endothelial cells start to produce growth factors like monocyte chemoattractant protein-1, which attracts inflammatory cells [51, 52]. These inflammatory cells adhere to the endothelium via adhesion molecules like vascular adhesion molecule 1 (VCAM-1) and move through the endothelium to the collaterals and produce cytokines and growth factors that support collateral growth and remodelling [53]. Several inflammatory cell types have been identified




Figure 3. Mechanism of arteriogenesis

(A) Without stenosis, there is no pressure gradient over pre-existing collateral capillaries, which are small and barely carry blood. **(B)** Development of a significant arterial obstruction leads to a drop in pressure and oxygen saturation distal in the vascular bed, while proximal pressure and oxygen saturation proximal remain normal. The pressure gradient over the collateral circulation increases fluid shear stress in these arterioles. **(C)** Widened collateral arteries restore distal perfusion and provide sufficiently oxygenated blood to distal tissues [96]. Adapted from: Stimulation of collateral artery growth: travelling further down the road to clinical application, Schirmer et al, Heart 2009.


to contribute to arteriogenesis; monocytes [54] and natural killer cells play an early role, while a variety of T-cell subsets arrive in a later phase [55]. The

arteriogenic process is further finished by extra maturation of the vessels. Proteases, like MMPs, produced by the invading cells, participate by degrading extracellular matrix creating space for the growing collaterals. Finally smooth muscles are attracted to the vascular wall stabilizing the widened collaterals [56]. A schematic overview of this process is shown in Figure 3.

It has to be noted that the above-described processes all play an important role in vascular formation and usually occur at the same time. All three mechanisms share common mechanisms like the expression of growth factors and cytokines and the invasion of (inflammatory) cells. As described before excessive or insufficient neovascularization can lead to a wide variety of diseases. Therefore it is of critical importance that the expression of the genes that are involved in the processes of angioadaptation is tightly regulated. In the next part of this general introduction an overview will be given of the most important steps that are taken at the post-transcriptional level of gene regulation.

Part II: Gene regulation at the posttranscriptional level

Proteins, which are built out of amino acids, have an extraordinary versatility to catalyze chemical reactions and build cellular structures. Deoxyribonucleic acid (DNA) is the cellular library that holds the information that prescribes and links the right amino acid sequence for each individual protein. This information is arranged in genes, which are transcribed into so-called messenger ribonucleic acid (mRNA) out of which proteins are synthesized. Transcription of a gene by RNA polymerase consists of several steps. After binding of the RNA polymerase to a promoter region of the DNA, the DNA switches from a closed to an open configuration. Opening up of the DNA gives RNA polymerase the ability to move along to DNA further downstream and transcribe the full mRNA that codes for the gene-encoded protein. During this elongation process the guiding DNA strand is subjected to binding of a wide variety of factors, like specificity factors, repressors, activators and enhancers, that can either promote or repress the synthesis of mRNA [57]. In recent years a next, epigenetic level of gene regulation has been described. Epigenetics is the study of heritable changes in gene expression or cellular phenotype by modifications, such as DNA methylation and histone deacetylation, both of which serve to suppress gene expression without altering the sequence of the silenced genes. These modifications make the DNA more and less accessible for enzyme complexes that drive gene transcription [58]. Interestingly, diet and environmental exposures can alter the level and activation of methyltransferases and deacetylases. Variety in these levels may be an explanation why cells and organisms with identical genotypes can have dramatic phenotypical differences. In addition, epigenetic modulation of gene expression may provide a link between lifestyle, gene expression and risk



of disease [59, 60].

Surprisingly, genomes of 'higher eukaryotes', like that of man and mouse, harbor about the same number of protein coding genes ($\pm 15,000$ and $20,000$) as the genomes of the apparently less complex 'lower eukaryotes' such as the round worm *Caenorhabditis elegans*. A likely explanation for this discrepancy is that more complex species have evolved following the development of advanced systems to regulate and coordinate the expression of the gene pool at the posttranscriptional level. A major fraction of the mechanisms of post-transcriptional gene regulation involves non-coding RNA transcripts. As only 1-2% of the total genome is responsible for the coding of proteins there appears to be ample space for the coding of RNAs transcripts that support post-transcriptional regulation [61].

The four main mechanisms of posttranscriptional gene regulation involve: 5' capping, polyadenylation, splicing and the regulation by non-coding RNAs. The first three processes take place in the nucleus and are schematically shown in Figure 4 and shortly described below. The regulation by non-coding RNAs is described in more detail in the second part of this general introduction as this is related to the main topic of this thesis.

5' capping

To be protected against RNA-viruses, such as a retrovirus, the cell harbors a variety of exonucleases that can degrade primary unmodified RNA molecules. To protect endogenous mRNAs from these enzymes the 5' end of the mRNA




Figure 4. Pre-mRNA processing

Eukaryotic genes are normally transcribed by RNA polymerase II as pre-mRNAs that must be processed before they are exported from the nucleus and translated into proteins. To protect endogenous mRNAs from these enzymes the 5' end of the mRNA is capped. Next, the poly(A) tail is required for protection against as well as export of the mRNA into the cytoplasm, furthermore the poly(A) tail is linked to the spliceosome. Splicing is the final step in the formation of a mature, functional mRNA. During this process non-coding introns are removed and exons are spliced together. Adapted from: Passmore Lab, MRC Laboratory of Molecular Biology, Cambridge UK.

is capped. This cap mimics the 3' end of the mRNA and is therefore protected against exonucleases that target the 5' start of RNA. Next to the protection against these enzymes, 5' capping also supports the export of the capped mRNA out of the nucleus, where it can undergo translation in the endoplasmic reticulum, where the 5' cap also functions as part of a docking station for the ribosome [57, 62, 63].


Polyadenylation

In animal cells, all mRNAs, have a 3' poly(A) tail, which consists of a homogenous long stretch of adenine bases. This poly(A) tail is important for the export of the mRNA out of the nucleus by poly(A) binding proteins and subsequent translation, furthermore the poly(A) tail protects the mRNA from enzymatic degradation [64]. Polyadenylation starts as soon as the transcription of the gene is completed. First, cleavage-and-polyadenylation specificity factor (CPF/CPSF) binds to a polyadenylation signal site (AAUAAA) and subsequently forms a loop with a GU rich sequence downstream of the polyadenylation signal [65]. Several cleavage factors then bind and stabilize this complex and then, with support of poly(A) polymerase, the RNA sequence is cleaved shortly downstream of the polyadenylation signal. Next, the cleavage factors and the downstream cleavage product are released and poly(A) polymerase adds residues to the 3' end of the RNA. This initial polyadenylation attracts the binding of poly(A)-binding protein II, which accelerates the rate of adenine addition, after around 250 adenine bases are added polymerization is stopped [66, 67].

Splicing

The polyadenylation complex is physically linked to the spliceosome, a complex that removes introns out of the RNA, in a process called splicing. Splicing is the final step in the formation of a mature, functional mRNA. During this process non-coding introns are removed and exons are spliced together. Splice sites are moderately conserved sequences at intron-exon boundaries, where the 5'-splice site consists mainly of GU bases and the 3'-splice site contains the complementary AG bases [68]. For splicing small nuclear ribonucleotide protein particles (snRNP) bind to the primary RNA transcript and to each other thereby catalyzing the transesterification of the 5'- and 3'-splice site. Upon this transesterification a subsequent reaction is catalyzed in which the intron is excised out of the primary RNA transcript and the two exons are fused. Upon fusion the snRNP-complex destabilizes and dissociates from the RNA [69].

Before splicing RNA transcripts can consist of multiple exons that may or may not all be needed for a functional protein. In this light, alternatively in- and exclusion of exons is very common in eukaryotic biology. Initially, the primary



transcripts of protein (isoforms) can be identical, while after complex splicing patterns several different mRNAs can be generated that lead to proteins with a different function, which also might be expressed at a totally different location [70, 71].

Non-coding RNAs

Until recently, 95% of our genome was considered to be 'junk-DNA', it was thought that this junk-DNA largely consisted of evolutionary artifacts and that untranscribable and untranslatable DNA was useful in a negative way (the importance of doing nothing) [72]. Large genomic and transcriptomic studies confirmed that only 1-2% of the mammalian genome corresponds to protein-coding genes and that the vast majority of the genome produces a wide variety of non-coding RNA transcripts. As such, RNA is not only a messenger operating between DNA and protein and might have more regulatory functions. Intriguingly, a linear relationship between the complexity of an organism and the number of produced non-coding RNAs has been indicated. This suggests that developmental complexity, which is not reflected in the number of protein coding genes, may be mediated by non-coding RNAs [73, 74].

A recently discovered group of large intergenic non-coding RNAs (lincRNAs) is receiving a growing recognition. At present only about a dozen lincRNAs are well characterized. These few lincRNAs show clear evolutionary conservation, confirming their potential important role in cell biology. Studies by Guttman et al. and Khalil et al. identified 3,289 lincRNAs and they speculate that their total number may well be in the range of 4,500. Although lincRNAs are among the least well understood of these transcript species, they cannot all be dismissed as merely transcriptional noise. Expression patterns suggest that lincRNAs are involved in diverse biological processes, including cell-cycle regulation, innate immunity and pluripotency. LincRNAs may act as molecular scaffolds that upon interaction with target proteins play regulatory roles in translation, splicing, nuclear organization and epigenetic gene expression. However, to date, clear mechanisms by which they have their influence are completely unknown [73, 75].

Short non-coding RNAs (microRNAs or miRNAs) have been described to play major roles in most, if not all, biological processes. MiRNAs are currently a well-established class of ~22 nucleotide endogenous, non-coding small RNAs that influence mRNA stability and translation [76]. MiRNA genes are transcribed by RNA polymerase II as capped and polyadenylated primary miRNA transcripts (pri-miRNA) [77, 78]. In the, so-called, canonical pathway, pri-miRNA processing occurs in two steps, catalyzed by two enzymes, Drosha and Dicer in cooperation with a dsRNA binding protein, DGCR8 [79]. In the first nuclear step, the Drosha–DGCR8 complex processes pri-miRNA into an ~70-nucleotide precursor hairpin (pre-miRNA), which is exported to the cytoplasm. Some pre-miRNAs are produced from very short introns (mirtrons) as a result of


splicing and debranching, thereby bypassing the Drosha–DGCR8 step [80, 81]. The nuclear export of pre-miRNAs is mediated by the transport receptor exportin 5 [82]. In the cytoplasm the pre-miRNA is matured by Dicer, assisted by a transactivation-responsive RNA-binding protein, into an imperfect RNA duplex [83]. The strand of the duplex with the weakest base pairing at the 5' terminus is preferably loaded into the miRNA-induced silencing complex (miRISC) [84]. Subsequently, the miRNA guides the miRISC to bind to the 3'UTR of their target sequence, thereby is the seed sequence (first 2 to 8 nucleotides) the most important sequence for target recognition and the consequential silencing of the mRNA [85, 86]. Translation of the mRNA is inhibited after association of miRISC with its target sequence. Efficient mRNA targeting requires continuous base pairing of miRNA nucleotides 2 to 8 (the seed region). Ago-proteins and glycine-tryptophan protein of 182 kDa (GW182) proteins are directly associated with miRNAs, are core components of the miRISC and are needed for effective translational repression (a schematic overview of miRNA biogenesis is shown in Figure 5). The exact mechanisms of translational arrest by the miRNA:mRNA complex is still a matter of debate, however both initiation and elongation steps of translation are thought to be affected [87-89].

It has become clear that during development many miRNAs are expressed in a tissue specific manner indicating that miRNAs may be involved in specifying and maintaining tissue identity [90]. For instance, miRNA-1, miRNA-133 and miRNA-206 are enriched in muscle tissue [91], miRNA-122 is well conserved between species in the liver [90, 92, 93] and the expression of miRNA-126 is enriched in the endothelium of human, mice [94], zebrafish [90] and cows [95]. The conservation between species suggests that the biological pathways where miRNAs play a role also may have been conserved, making them research targets of high interest.

The enriched expression of miRNA-126 in endothelial cells combined with the fact that these cells are key players during the control of vascular integrity makes the detailed analysis of the biological mechanisms controlled by this miRNA a research topic of high interest and relevance. Understanding the role that miRNA-126 plays in vascular homeostasis may lead to new insights and possible new therapeutic developments.

Scope of thesis

This thesis details our studies assessing the role of the endothelial-enriched miRNA-126 in the regulation of vascular homeostasis. In **Chapter 2** the current insight in the role of miRNA-126 in vascular homeostasis is reviewed. **Chapter 3** focuses on the role of miRNA-126 in ischemia induced angiogenesis, followed by **Chapter 4** which describes the potential role of miRNA-126 the mobilization of vasculogenic progenitor cells upon ischemia.







Figure 5. MicroRNA biogenesis

Figure 5. MicroRNA biogenesis

MicroRNAs (miRNAs) are processed from RNA polymerase II (RNAPII)-specific transcripts of independent genes or from introns of protein-coding genes. In the canonical pathway, primary precursor (pri-miRNA) processing occurs in two steps, catalyzed by two members of the RNase III family of enzymes, Drosha and Dicer in cooperation with dsRNA binding protein DGCR8. In the first nuclear step, the Drosha–DGCR8 complex processes pri-miRNA into an ~70-nucleotide precursor hairpin (pre-miRNA), which is exported to the cytoplasm. Some pre-miRNAs are produced from very short introns (mirtrons) as a result of splicing and debranching, thereby bypassing the Drosha–DGCR8 step. In either case, cleavage by Dicer, assisted by transactivation-responsive RNA-binding protein (TRBP), in the cytoplasm yields an ~20 bp miRNA/miRNA* duplex. In mammals, Argonaute 2 (Ago2) support Dicer processing by cleaving the 3' arm of some pre-miRNAs, forming an additional processing intermediate called AGO2-cleaved precursor miRNA (ac-pre-miRNA). Following processing, one strand of the miRNA/miRNA* duplex (the guide strand) is preferentially incorporated into an miRNA-induced silencing complex (miRISC), whereas the other strand (passenger or miRNA*) is released and degraded, in some cases this passenger strand can also be loaded into miRISC to function as miRNAs. Most animal miRNAs imperfectly base-pair with sequences in the 3'-UTR of target mRNAs, and inhibit protein synthesis by either repressing translation or promoting mRNA deadenylation and decay. Efficient mRNA targeting requires continuous base-pairing of miRNA nucleotides 2 to 8 (the seed region). Ago-proteins and glycine-tryptophan protein of 182 kDa (GW182) proteins are directly associated with miRNAs, are core components of the miRNA-induced silencing complex and are needed for effective binding and subsequent translational repression or a decay [80]. Adapted from: The widespread regulation of microRNA biogenesis, function and decay, Krol et al, Nature Reviews Genetics, 2010.

Both chapters utilize antagomir-technology to specifically silence miRNA-126 *in vivo*. This approach to silence miRNA-126 was also used in **Chapter 5** to elucidate the regulatory role of miRNA-126 in vascular cell adhesion molecule-1 expression in the kidney vasculature. **Chapter 6** details our findings that circulating miRNA-126 in the periphery is not exclusively derived from endothelial cells but can also originate from platelets. Consequently, the use of aspirin has to be taken into account when relating circulating miRNA-126 levels to the progression of cardiovascular disease. **Chapter 7** demonstrates that the angiogenic potential of miRNA-126 as described in Chapter 3 might reach beyond the presence of this pro-angiogenic miRNA in endothelium, but that neovascularization can also be supported by miRNA-126 expressed in circulating cells.


Finally, **Chapter 8** provides a summary of research presented in this thesis, presents the major conclusions that could be drawn and further discusses the role of miRNA-126 in vascular homeostasis.



References

1. World Health Organization (<http://www.who.int>). In: 2011.
2. Carmeliet P. Angiogenesis in health and disease. *Nat Med* 2003;9:653-60.
3. Zakrzewicz A, Secomb TW, Pries AR. Angioadaptation: keeping the vascular system in shape. *News Physiol Sci* 2002;17:197-201.
4. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nat Med* 2000;6:389-95.
5. Baron MH. Embryonic origins of mammalian hematopoiesis. *Exp Hematol* 2003;31:1160-9.
6. Hirschi K, Goodell M. Common origins of blood and blood vessels in adults? *Differentiation* 2001;68:186-92.
7. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. *Am J Physiol Cell Physiol* 2004;287:C572-C579.
8. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275:964-7.
9. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, et al. Evidence for circulating bone marrow-derived endothelial cells. *Blood* 1998;92:362-7.
10. Yoder MC. Defining human endothelial progenitor cells. *J Thromb Haemost* 2009;7 Suppl 1:49-52.
11. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 1999;85:221-8.
12. de Boer HC, Verseyden C, Ulfman LH, Zwaginga JJ, Bot I, Biessen EA, et al. Fibrin and activated platelets cooperatively guide stem cells to a vascular injury and promote differentiation towards an endothelial cell phenotype. *Arterioscler Thromb Vasc Biol* 2006;26:1653-9.
13. Op den Buijs J, Musters M, Verrips T, Post JA, Braam B, van Riel N. Mathematical modeling of vascular endothelial layer maintenance: the role of endothelial cell division, progenitor cell homing, and telomere shortening. *Am J Physiol Heart Circ Physiol* 2004;287:H2651-H2658.
14. Rafii S, Skobe M. Splitting vessels: keeping lymph apart from blood. *Nat Med* 2003;9:166-8.
15. Tepper OM, Capla JM, Galiano RD, Ceradini DJ, Callaghan MJ, Kleinman ME, et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. *Blood* 2005;105:1068-77.
16. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med* 2003;348:593-600.
17. Kunz GA, Liang G, Cuculi F, Gregg D, Vata KC, Shaw LK, et al. Circulating endothelial progenitor cells predict coronary artery disease severity. *Am Heart J* 2006;152:190-5.
18. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. *Diabetes* 2004;53:195-9.
19. de Boer HC, Hovens MM, van Oeveren-Rietdijk AM, Snoep JD, de Koning EJ, Tamsma JT, et al. Human CD34+/KDR+ cells are generated from circulating CD34+ cells after immobilization on activated platelets. *Arterioscler Thromb Vasc Biol* 2011;31:408-15.
20. Liew A, Barry F, O'Brien T. Endothelial progenitor cells: diagnostic and therapeutic considerations. *Bioessays* 2006;28:261-70.
21. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 2001;89:E1-E7.
22. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. *Circ Res* 2004;95:343-53.
23. Botta R, Gao E, Stassi G, Bonci D, Pelosi E, Zwas D, et al. Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. *FASEB J* 2004;18:1392-4.
24. Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, et al. Dose-de-

- pendent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. *Circulation* 2006;113:1311-25.
25. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. *Circulation* 2001;103:634-7.
 26. Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. *Circulation* 2003;107:461-8.
 27. Kawamoto A, Iwasaki H, Kusano K, Murayama T, Oyamada A, Silver M, et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. *Circulation* 2006;114:2163-9.
 28. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 2001;7:430-6.
 29. Zhang S, Ge J, Zhao L, Qian J, Huang Z, Shen L, et al. Host vascular niche contributes to myocardial repair induced by intracoronary transplantation of bone marrow CD34+ progenitor cells in infarcted swine heart. *Stem Cells* 2007;25:195-203.
 30. Yoshioka T, Ageyama N, Shibata H, Yasu T, Misawa Y, Takeuchi K, et al. Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34+ stem cells in a nonhuman primate model. *Stem Cells* 2005;23:355-64.
 31. Mackie AR, Losordo DW. CD34-Positive Stem Cells in the Treatment of Heart and Vascular Disease in Human Beings. *Tex Heart Inst J* 2011;38:474-85.
 32. Rosinberg A, Khan TA, Sellke FW, Laham RJ. Therapeutic angiogenesis for myocardial ischemia. *Expert Rev Cardiovasc Ther* 2004;2:271-83.
 33. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet* 2002;360:427-35.
 34. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer* 2003;3:401-10.
 35. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. *Curr Opin Genet Dev* 2007;17:71-7.
 36. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol Cell Biol* 1996;16:4604-13.
 37. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. *J Clin Invest* 1998;101:2567-78.
 38. Coulon C, Georgiadou M, Roncal C, De BK, Langenberg T, Carmeliet P. From vessel sprouting to normalization: role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery. *Arterioscler Thromb Vasc Biol* 2010;30:2331-6.
 39. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. *Cancer Res* 1986;46:467-73.
 40. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhodzij S, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. *Blood* 2010;116:829-40.
 41. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. *Nat Rev Mol Cell Biol* 2007;8:464-78.
 42. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. *Nature* 2011;473:298-307.
 43. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in



- patients with critical limb ischemia. *Circulation* 1998;97:1114-23.
44. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. *J Vasc Surg* 1998;28:964-73.
 45. Kim HJ, Jang SY, Park JI, Byun J, Kim DI, Do YS, et al. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. *Exp Mol Med* 2004;36:336-44.
 46. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. *Circulation* 2001;104:753-5.
 47. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. *J Am Coll Cardiol* 2003;42:1339-47.
 48. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. *Circulation* 2003;107:1359-65.
 49. Rajagopalan S, Mohler ER, III, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. *Circulation* 2003;108:1933-8.
 50. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. *Circulation* 2002;105:788-93.
 51. Hoefler IE, Grundmann S, van Royen N, Voskuil M, Schirmer SH, Ullmans S, et al. Leukocyte subpopulations and arteriogenesis: specific role of monocytes, lymphocytes and granulocytes. *Atherosclerosis* 2005;181:285-93.
 52. Lee CW, Stabile E, Kinnaird T, Shou M, Devaney JM, Epstein SE, et al. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. *J Am Coll Cardiol* 2004;43:474-82.
 53. Hoefler IE, van Royen N, Buschmann IR, Piek JJ, Schaper W. Time course of arteriogenesis following femoral artery occlusion in the rabbit. *Cardiovasc Res* 2001;49:609-17.
 54. Schaper W, Flameng W, Winkler B, Wusten B, Turschmann W, Neugebauer G, et al. Quantification of collateral resistance in acute and chronic experimental coronary occlusion in the dog. *Circ Res* 1976;39:371-7.
 55. van Weel V, Toes RE, Seghers L, Deckers MM, de Vries MR, Eilers PH, et al. Natural killer cells and CD4+ T-cells modulate collateral artery development. *Arterioscler Thromb Vasc Biol* 2007;27:2310-8.
 56. Palumbo R, Gaetano C, Antonini A, Pompilio G, Bracco E, Ronnstrand L, et al. Different effects of high and low shear stress on platelet-derived growth factor isoform release by endothelial cells: consequences for smooth muscle cell migration. *Arterioscler Thromb Vasc Biol* 2002;22:405-11.
 57. Lodish HF, Berk AD, Zipursky SL, Matsudaira PT, Baltimore D, Darnell JE. *Molecular Cell Biology*. 1986.
 58. Gibney ER, Nolan CM. Epigenetics and gene expression. *Heredity (Edinb)* 2010;105:4-13.
 59. Hamilton JP. Epigenetics: principles and practice. *Dig Dis* 2011;29:130-5.
 60. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. *Nat Rev Genet* 2007;8:253-62.
 61. Carninci P, Hayashizaki Y. Noncoding RNA transcription beyond annotated genes. *Curr Opin Genet Dev* 2007;17:139-44.
 62. Kapp LD, Lorsch JR. The molecular mechanics of eukaryotic translation. *Annu Rev Biochem*

- 2004;73:657-704.
63. Lodish HF, Bergmann JE, Alton TH. Regulation of messenger RNA translation. *Brookhaven Symp Biol* 1977;309-31.
 64. Guhaniyogi J, Brewer G. Regulation of mRNA stability in mammalian cells. *Gene* 2001;265:11-23.
 65. Wahle E, Keller W. The biochemistry of 3'-end cleavage and polyadenylation of messenger RNA precursors. *Annu Rev Biochem* 1992;61:419-40.
 66. Wahle E. Poly(A) tail length control is caused by termination of processive synthesis. *J Biol Chem* 1995;270:2800-8.
 67. Viphakone N, Voisinet-Hakil F, Minvielle-Sebastia L. Molecular dissection of mRNA poly(A) tail length control in yeast. *Nucleic Acids Res* 2008;36:2418-33.
 68. Black DL. Finding splice sites within a wilderness of RNA. *RNA* 1995;1:763-71.
 69. Newman A. RNA splicing. *Curr Biol* 1998;8:R903-R905.
 70. Lopez AJ. Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. *Annu Rev Genet* 1998;32:279-305.
 71. Wang ET, Sandberg R, Luo S, Khrebtkova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. *Nature* 2008;456:470-6.
 72. Ohno S. So much "junk" DNA in our genome. *Brookhaven Symp Biol* 1972;23:366-70.
 73. Khalil AM, Rinn JL. RNA-protein interactions in human health and disease. *Semin Cell Dev Biol* 2011.
 74. Taft RJ, Pheasant M, Mattick JS. The relationship between non-protein-coding DNA and eukaryotic complexity. *Bioessays* 2007;29:288-99.
 75. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature* 2009;458:223-7.
 76. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. *Dev Cell* 2006;11:441-50.
 77. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. *RNA* 2004;10:1957-66.
 78. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. *EMBO J* 2004;23:4051-60.
 79. Yeom KH, Lee Y, Han J, Suh MR, Kim VN. Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. *Nucleic Acids Res* 2006;34:4622-9.
 80. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. *Nat Rev Genet* 2010;11:597-610.
 81. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature* 2003;425:415-9.
 82. Kim VN. MicroRNA precursors in motion: exportin-5 mediates their nuclear export. *Trends Cell Biol* 2004;14:156-9.
 83. Hammond SM. Dicing and slicing: the core machinery of the RNA interference pathway. *FEBS Lett* 2005;579:5822-9.
 84. Hutvagner G. Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. *FEBS Lett* 2005;579:5850-7.
 85. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. *Genes Dev* 2004;18:504-11.
 86. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005;120:15-20.
 87. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. *Mol Cell* 2006;21:533-42.
 88. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. *Science* 2005;309:1573-6.

89. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nat Rev Genet* 2011;12:99-110.
90. Wienholds E, Kloosterman WJP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E, et al. MicroRNA expression in zebrafish embryonic development. *Science* 2005;309:310-1.
91. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. *Nat Genet* 2006;38:228-33.
92. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. *Science* 2005;309:1577-81.
93. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel WW, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. *J Cell Biochem* 2006;99:671-8.
94. van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk AM, et al. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. *J Cell Mol Med* 2009;13:1577-85.
95. Hossain MM, Ghanem N, Hoelker M, Rings F, Phatsara C, Tholen E, et al. Identification and characterization of miRNAs expressed in the bovine ovary. *BMC Genomics* 2009;10:443.
96. Schirmer SH, van Nooijen FC, Piek JJ, van RN. Stimulation of collateral artery growth: travelling further down the road to clinical application. *Heart* 2009;95:191-7